This year, "double 11", CFDA issued the "8 companies on 11 applications for drug registration approval" (2015 229th), so that the entire pharmaceutical industry shocked. However, the day before the double 11, the highest national leaders for the first time put forward "supply side structural reforms", half a month so far has frequently stressed that "supply side reforms" have recently become one of the hot areas of economic Chinese words.
For the pharmaceutical industry, the rationale for this year, CFDA and other ministries promulgated a series of announcements and policies, you can find that the pharmaceutical industry is from research and development, production and procurement of 3 aspects of the "supply side" reform". It can be foreseen that the supply side reform of the pharmaceutical industry in the future will only strengthen, and there is no possibility of backing off.

• Previous: none
• Next: Sophisticated bio me...